Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.84 |
| ▸ | PDE5A | O76074 | 5/20 | 0.84 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.84 |
| ▸ | PDE11A | Q9HCR9 | 5/20 | 0.84 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.84 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.84 |
| ▸ | PDE2A | O00408 | 4/20 | 0.84 |
| ▸ | PDE8A | O60658 | 4/20 | 0.84 |
| ▸ | PDE9A | O76083 | 3/20 | 0.79 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366408 | 1.00 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL24066896 | 0.98 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8052910 | 0.94 | PDE4A (0.79) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201377 | 0.93 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL17366407 | 0.93 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL17521214 | 0.91 | PDE4A (0.87) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL19134017 | 0.91 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL4920743 | 0.91 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201378 | 0.91 | PDE4A (0.78) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201366 | 0.89 | PDE4A (0.92) | PDE4APDE5APDE3BPDE11APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220280517-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11291666-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210338679-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210213018-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20200375994-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-09-17 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2939676-A1 | Organic compounds | Intra-Cellular Therapies, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140357606-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-04 | — | — | US | disclosed |
| EP-2698160-A2 | Organic compounds | Takeda Pharmaceutical Company Limited (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8273751-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2009075784-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE5A 1/4885PDE3B 7/4885 |
| US-20230355625-A1 | METHODS OF TREATMENT | PDE1A, PDE1B, PDE7A | PDE4A 4/4885PDE5A 11/4885PDE3B 18/4885 |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | GAP43, NGF, CHAT | PDE4A 236/4885PDE5A 443/4885PDE3B 320/4885 |
| US-20100273754-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-20210338679-A1 | NOVEL USES | PDE2A, PDE7A, PDE4A | PDE4A 3/4885PDE5A 5/4885PDE3B 7/4885 |
| US-20140357606-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE4A 9/4885PDE5A 1/4885PDE3B 5/4885 |
| US-20120238589-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-20210213018-A1 | NOVEL USES | PDE2A, PDE4A, PDE1A | PDE4A 2/4885PDE5A 6/4885PDE3B 9/4885 |
| US-20200375994-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE5A 28/4885PDE3B 53/4885 |
| US-11291666-B2 | Uses | PDE2A, PDE3A, PDE5A | PDE4A 4/4885PDE5A 3/4885PDE3B 5/4885 |
| US-20230338385-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | PDE4A 11/4885PDE5A 14/4885PDE3B 21/4885 |
| US-20220280517-A1 | ORGANIC COMPOUNDS | PDE3A, PDE3B, PDE2A | PDE4A 11/4885PDE5A 4/4885PDE3B 2/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE4A 10/4885PDE5A 1/4885PDE3B 6/4885 |
| US-11759465-B2 | Uses | ADORA2A, ADORA2B, ADORA1 | PDE4A 12/4885PDE5A 15/4885PDE3B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.